Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study

References

• TashkinDP, PearleJ, IezzoniD, et al. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD. 2009;6(1):17–25.19229704
   PubMedGoogle Scholar
• van NoordJA, AumannJL, JanssensE, et al. Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respir Med. 2010;104(7):995–1004. doi:10.1016/j.rmed.2010.02.01720303247
   PubMed Web of Science ®Google Scholar
• van NoordJA, AumannJL, JanssensE, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest. 2006;129(3):509–517. doi:10.1378/chest.129.3.50916537846
   PubMed Web of Science ®Google Scholar
• PriceD, OstremA, ThomasM, et al. Dual bronchodilation in COPD: lung function and patient-reported outcomes – a review. Int J Chron Obstruct Pulmon Dis. 2017;12:141–168. doi:10.2147/COPD.S11671928115839
   PubMed Web of Science ®Google Scholar
• NiciL, MammenMJ, CharbekE, et al. Pharmacologic management of chronic obstructive pulmonary disease: an official American thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56–e69. doi:10.1164/rccm.202003-0625ST32283960
   PubMed Web of Science ®Google Scholar
• TashkinDP, StrangeC. Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy? Int J Chron Obstruct Pulmon Dis. 2018;13:2587–2601. doi:10.2147/COPD.S17224030214177
   PubMed Web of Science ®Google Scholar
• SiddiquiSH, PavordID, BarnesNC, et al. Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis. 2018;13:3669–3676. doi:10.2147/COPD.S17942530464449
   PubMed Web of Science ®Google Scholar
• GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease - 2019 report. Chronic Obstr Pulm Dis. 2019.
   Web of Science ®Google Scholar
• WedzichaJA, BanerjiD, ChapmanKR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234. doi:10.1056/NEJMoa151638527181606
   PubMed Web of Science ®Google Scholar
• LipsonDA, BarnhartF, BrealeyN, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680.29668352
   PubMed Web of Science ®Google Scholar
• SuissaS, DrazenJM. Making sense of triple inhaled therapy for COPD. N Engl J Med. 2018;378(18):1723–1724. doi:10.1056/NEJMe171680229669218
   PubMed Web of Science ®Google Scholar
• BousquetJ, PoliG, AcerbiD, et al. Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination. Clin Pharmacokinet. 2009;48:347–358.19650674
   PubMed Web of Science ®Google Scholar
• PostmaDS, RocheN, ColiceG, et al. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:1163–1186.25378918
   PubMed Web of Science ®Google Scholar
• SonnappaS, MartinR, IsraelE, et al. Risk of pneumonia in obstructive lung disease: a real-life study comparing extrafine and fine-particle inhaled corticosteroids. PLoS One. 2017;12:e0178112.28617814
   PubMed Web of Science ®Google Scholar
• KerkhofM, SonnappaS, PostmaDS, et al. Blood eosinophil count and exacerbation risk in patients with COPD. Eur Respir J. 2017;50(1).
   PubMed Web of Science ®Google Scholar
• BafadhelM, PetersonS, De BlasMA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117–126. doi:10.1016/S2213-2600(18)30006-729331313
   PubMed Web of Science ®Google Scholar
• KerkhofM, FreemanD, JonesR, ChisholmA, PriceDB. Predicting frequent COPD exacerbations using primary care data. Int J Chron Obstruct Pulmon Dis. 2015;10:2439–2450.26609229
   PubMed Web of Science ®Google Scholar
• BelhassenM, NibberA, Van GanseE, et al. Inappropriate asthma therapy-a tale of two countries: a parallel population-based cohort study. NPJ Prim Care Respir Med. 2016;26(1):16076. doi:10.1038/npjpcrm.2016.7627735927
   PubMed Web of Science ®Google Scholar
• HalpinDM, KerkhofM, SorianoJB, et al. Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. Respir Res. 2016;17(1):120. doi:10.1186/s12931-016-0433-527663386
   PubMed Web of Science ®Google Scholar
• QuintJK, MullerovaH, DiSantostefanoRL, et al. Validation of chronic obstructive pulmonary disease recording in the clinical practice research datalink (CPRD-GOLD). BMJ Open. 2014;4(7):e005540. doi:10.1136/bmjopen-2014-005540
   PubMed Web of Science ®Google Scholar
• SchneeweissS, RassenJA, BrownJS, et al. Graphical depiction of longitudinal study designs in health care databases. Ann Intern Med. 2019;170(6):398–406. doi:10.7326/M18-307930856654
   PubMed Web of Science ®Google Scholar
• AlthunianTA, de BoerA, GroenwoldRH, et al. Defining the noninferiority margin and analysing noninferiority: an overview. Br J Clin Pharmacol. 2017;83(8):1636–1642. doi:10.1111/bcp.1328028252213
   PubMed Web of Science ®Google Scholar
• HolmS. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65–70.
   Web of Science ®Google Scholar
• SuissaS, Dell’AnielloS, ErnstP. Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in real-world clinical practice. Chest. 2019;155(6):1158–1165. doi:10.1016/j.chest.2019.03.00530922950
   PubMed Web of Science ®Google Scholar
• RennardS, DecramerM, CalverleyPM, et al. Impact of COPD in North America and Europe in 2000: subjects’ perspective of confronting COPD international survey. Eur Respir J. 2002;20(4):799‐805. doi:10.1183/09031936.02.03242002
   PubMed Web of Science ®Google Scholar
• (eMC) TeMC. Foster 100/6 Inhalation Solution - Summary of Product Characteristics. 2018.
   Google Scholar
• SuissaS, Dell’AnielloS, ErnstP. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respir Med. 2018;6(11):855–862. doi:10.1016/S2213-2600(18)30368-030343028
   PubMed Web of Science ®Google Scholar
• SouthworthT, BeechG, FodenP, et al. The reproducibility of COPD blood eosinophil counts. Eur Respir J. 2018;52(1):1800427. doi:10.1183/13993003.00427-201829724922
   PubMed Web of Science ®Google Scholar
• LandisSH, SurukiR, HiltonE, ComptonC, GalweyNW. Stability of blood eosinophil count in patients with COPD in the UK clinical practice research datalink. COPD. 2017;14(4):382–388. doi:10.1080/15412555.2017.131382728569614
   PubMedGoogle Scholar